Los Angeles Capital Management LLC Trims Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

Los Angeles Capital Management LLC reduced its position in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 47.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,940 shares of the company's stock after selling 24,923 shares during the period. Los Angeles Capital Management LLC's holdings in Denali Therapeutics were worth $814,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. Assetmark Inc. grew its stake in Denali Therapeutics by 18.0% in the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company's stock valued at $111,000 after acquiring an additional 580 shares during the period. AIA Group Ltd raised its stake in Denali Therapeutics by 7.9% during the third quarter. AIA Group Ltd now owns 74,815 shares of the company's stock worth $2,179,000 after purchasing an additional 5,471 shares during the period. Principal Financial Group Inc. grew its position in Denali Therapeutics by 13.8% in the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock worth $36,076,000 after acquiring an additional 149,939 shares during the period. VELA Investment Management LLC acquired a new stake in shares of Denali Therapeutics during the 3rd quarter worth about $455,000. Finally, MONECO Advisors LLC increased its position in shares of Denali Therapeutics by 4.6% during the third quarter. MONECO Advisors LLC now owns 9,100 shares of the company's stock valued at $265,000 after acquiring an additional 400 shares during the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DNLI has been the topic of several research reports. Raymond James reissued a "market perform" rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Wedbush dropped their price objective on Denali Therapeutics from $30.00 to $26.00 and set an "outperform" rating on the stock in a report on Friday, August 2nd. JPMorgan Chase & Co. reduced their target price on Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating for the company in a report on Friday, October 11th. Jefferies Financial Group boosted their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Friday, November 1st. Finally, Citigroup raised their price objective on shares of Denali Therapeutics from $26.00 to $32.00 and gave the stock a "buy" rating in a research report on Friday, August 2nd. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $38.90.

Denali Therapeutics Stock Down 12.0 %

Shares of Denali Therapeutics stock traded down $3.40 on Friday, hitting $25.05. The company's stock had a trading volume of 1,103,219 shares, compared to its average volume of 1,070,498. The company has a market capitalization of $3.61 billion, a P/E ratio of -9.08 and a beta of 1.40. The firm has a fifty day moving average price of $28.20 and a 200-day moving average price of $23.97. Denali Therapeutics Inc. has a 52-week low of $14.56 and a 52-week high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same quarter in the previous year, the firm earned ($0.72) earnings per share. As a group, analysts expect that Denali Therapeutics Inc. will post -2.69 earnings per share for the current year.

Insider Buying and Selling

In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the company's stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $29.03, for a total transaction of $870,900.00. Following the completion of the sale, the director now directly owns 29,096 shares in the company, valued at $844,656.88. This represents a 50.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Alexander O. Schuth sold 15,558 shares of Denali Therapeutics stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $29.91, for a total value of $465,339.78. Following the completion of the transaction, the insider now directly owns 178,066 shares in the company, valued at $5,325,954.06. This represents a 8.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 86,578 shares of company stock worth $2,474,440. 7.90% of the stock is owned by insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.